Table 2

List of the 43 meta-analyses that were used in the empirical evaluation

ID

Reference

Gene/Locus

Disease/Outcome

SNPs in haplotype

Number of studies

Sample Size

Method of analysis

Data availability

Collaborative analysis

Significant results


1

[109]

DRD3

Schizophrenia

4

5

7551

1 vs. others

No

No

No

2

[98]

ITGAV

Rheumatoid Arthritis

3

3

6851

N/A

Yes

Yes

Yes

3

[110]

IL1A/IL1B/IL1RN

Osteoarthritis

7

4

2908

1 vs. others

No

Yes

Yes

4

[111]

FRZB

Osteoarthritis

2

10

12380

1 vs. others

No

Yes

No

5

[99]

CX3CR1

CAD

2

6

2912

1 vs. others

Yes

No

Yes

6

[112]

ALOX5AP

Stroke

4

5

5765

1 vs. others

No

No

No

7

[112]

ALOX5AP

Stroke

4

3

3004

1 vs. others

No

No

No

8

[113]

GNAS

Malaria

3

7

8154

1 vs. others

No

Yes

Yes

9

[113]

GNAS

Malaria

7

6

7632

1 vs. others

No

Yes

Yes

10

[114]

PDLIM5

Bipolar Disorder

2

3

1208

1 vs. others

No

No

No

11

[115]

PDE4D

Stroke

2

4

4961

1 vs. others

No

No

Yes

12

[116]

TGFB1

Renal Transplantation

2

4

438

pooled

No

No

Yes

13

[116]

IL10

Renal Transplantation

3

4

348

pooled

No

No

No

14

[117]

9p21.3

CAD

4

5

7838

1 vs. others

No

Yes

Yes

15

[118]

HLA

SLE

2

3

527

1 vs. others

No

No

Yes

16

[94]

CTLA4

Graves Disease

2

10

2564

1 vs. others

Yes

Yes

Yes

17

[94]

CTLA4

Hashimoto Thyroiditis

2

5

1210

1 vs. others

Yes

Yes

Yes

18

[119]

ENPP1

T2DM

3

3

8676

1 vs. others

No

No

No

19

[77]

MTHFR

ALL

2

4

894

Log-linear model

No

No

Yes

20

[97]

CAPN10

T2DM

3

11

5862

1 vs. others

Yes

Yes

Yes

21

[93]

ADAM33

Asthma

5

3

1899

pooled

Yes

No

No

22

[120]

NRG1

Schizophrenia

6

11

8722

1 vs. others

No

No

Yes

23

[121]

RGS4

Schizophrenia

4

8

7243

1 vs. others

No

Yes

No

24

[122]

ADRB2

Asthma

2

3

2060

N/A

No

No

Yes

25

[123]

ESR1

Fractures

3

8

14622

1 vs. others

No

Yes

Yes

26

[78]

VDR

Osteoporosis

3

4

2335

Log-linear model

Yes

No

Yes

27

[95]

ACE

Alzheimer's Disease

3

4

1619

pooled

Yes

Yes

Yes

28

[124]

IGF-I

IGF-I levels

3

3

1929

1 vs. others

No

Yes

Yes

29

[125]

TF

Stroke

2

2

818

N/A

No

Yes

No

30

[92]

FcgammaR

Celliac Disease

2

2

1057

N/A

Yes

Yes

No

31

[69]

VDR

Fractures

3

9

23309

Logistic regression

No

Yes

No

32

[96]

G72/G30

Schizophrenia

2

2

1541

N/A

Yes

Yes

Yes

33

[68]

VEGF

ALS

3

4

1912

Logistic regression

Yes

Yes

Yes

34

[126]

BANK1

Rheumatoid Arthritis

3

4

4445

1 vs. others

No

Yes

Yes

35

[67]

CYP19A1

Endometrial Cancer

2

10

13283

Logistic regression

No

Yes

Yes

36

[127]

CRP

T2DM

3

3

11876

N/A

No

No

Yes

37

[66]

8q24

Colorectal Adenoma

4

3

5385

Logistic regression

No

Yes

Yes

38

[128]

CYP1A1

Lung Cancer

2

13

2151

Pooled

No

Yes

Yes

39

[91]

TNFA

Prostate Cancer

5

2

4881

Pooled

Yes

Yes

No

40

[90]

PTGS2

Prostate Cancer

4

2

4881

Pooled

Yes

Yes

No

41

[129]

AR

Endometrial Cancer

5

2

1424

Pooled

No

Yes

No

42

[130]

MGMT

Head and Neck Cancer

2

3

1347

Pooled

No

Yes

No

43

[131]

SNCA

Parkinson Disease

2

11

5344

1 vs. other

No

Yes

Yes


We list the reference, the gene name, the disease, the number of SNPs included in the haplotypes, the number of studies, the total sample size, the method of analysis (N/A: not available), the availability of data, whether the data was collected in a collaborative setting and whether the study reported significant results.

Bagos BMC Genetics 2011 12:8   doi:10.1186/1471-2156-12-8

Open Data